Gilead’s Trodelvy secures EC approval for Metastatic TNBC treatment

Gilead Sciences has received marketing authorisation from the European Commission (EC) for Trodelvy (sacituzumab govitecan) to treat adult patients suffering from unresectable or metastatic triple-negative breast cancer (TNBC).